2025 COPD Management: Insights for Critical Care Physicians

Welcome to Medical Specialists Associates’ educational series on topics in Critical Care Medicine. I’m Christopher Voss, MD, MS, FCCP, board-certified in Anesthesiology, Critical Care, and Neurocritical Care Medicine. Chronic Obstructive Pulmonary Disease (COPD) remains a leading cause of morbidity and mortality globally. It is a heterogeneous condition characterized by persistent, often progressive, airflow obstruction and is influenced by both environmental and genetic factors. Today, we will explore the latest evidence and recommendations from the 2025 GOLD report, highlighting key updates in the diagnosis, management, and prevention of COPD. References 1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD (2025 Report). GOLD; 2024. 2. Vogelmeier CF, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2025;201:xx-xx. 3. Han MK, et al. Role of biomarkers in guiding treatment decisions in COPD. Lancet Respir Med. 2024;xx(xx):xx-xx. 4. Ding Z, Li X, Lu Y, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2016;121:39–47.